Abstract
INTRODUCTION
The prevalence of aortic valve disease continues to increase as the global population ages and life expectancy continues to rise [1, 2] . Bioprosthetic aortic valve tissue made from bovine pericardium is increasingly implanted, due its demonstrated longevity and reliable haemodynamic performance. Additionally, aortic valve replacement (AVR) with bioprosthetic tissue avoids the long-term anticoagulation necessary with mechanical valves [3] [4] [5] . The durability of the Carpentier-Edwards PERIMOUNT TM bovine pericardial bioprosthesis platform has been demonstrated by a low rate of valve-related adverse events including structural valve deterioration (SVD) with an expected valve durability of up to 20 years [6] . In patients under 60 years of age, the risk of SVD and reoperation due to tissue failure as a result of calcification is higher, emphasizing the need for a more durable valve in younger patients with longer life expectancy [7] [8] [9] . Calcification plays a major role in SVD and eventual failure of bioprosthetic heart valve tissue. Tissue calcification is understood to be primarily due to chemical processes between glutaraldehyde and free aldehydes, remnants of the tissue treatment process and their interaction with free calcium in the circulating blood. Other factors contributing to SVD are patient comorbidities such as hyperparathyroidism, diabetes mellitus and renal disease [10, 11] .
The study valve investigated here builds upon the design of the Carpentier-Edwards PERIMOUNT TM Magna Ease TM valve and incorporates RESILIA TM tissue, a bovine pericardial tissue that incorporates a novel preservation technology, which permanently blocks residual aldehyde groups known to bind to calcium, and preserves tissue with glycerol, allowing dry storage of the valve prior to surgical implantation. This avoids re-exposure to glutaraldehyde during storage and obviates the need to rinse the valve during surgical preparation. The performance of this tissue has been evaluated in an intramuscular rabbit study and demonstrated that RESILIA TM significantly reduced both free aldehyde content and tissue calcification [12] . In juvenile sheep, mitral bioprosthetic valves with RESILIA TM tissue demonstrated a statistically significant reduction in leaflet calcification (P = 0.002) and significant improvement in haemodynamic performance (P = 0.03) over commercially available pericardial tissue valves (Carpentier-Edwards PERIMOUNT PLUS TM Pericardial Mitral Bioprosthesis, Model 6900P) [13] . Early clinical experience with this novel tissue is encouraging [14] . We here report the 2-year results of the COMMENCE trial, evaluating the safety and performance of RESILIA TM tissue in a prospective, non-randomized, multicentre study of patients undergoing AVR.
MATERIALS AND METHODS
The COMMENCE Trial is a prospective, non-randomized, multicentre clinical evaluation of the Edwards Pericardial Aortic Bioprosthesis, Model 11000A, which features a new pericardial tissue (RESILIA TM ) in subjects who require surgical replacement of their native or prosthetic aortic valve. All study subjects were enrolled at 27 clinical sites in the USA and Poland (Supplementary Material, Table S1 ) and followed for 1 year to assess primary safety and effectiveness and annually thereafter for a minimum of 5 years after the index operation. The present data set (locked 13 April 2016) includes 857 patient-years of total follow-up, including 800.9 patient-years of late (>30 days) follow-up, with mean followup of 1 
Study device
The study valve is a trileaflet bioprosthesis comprised of bovine pericardium mounted on a flexible frame. The physical structure and design of the Model 11000 A is identical to the CarpentierEdwards PERIMOUNT TM Magna Ease TM platform. RESILIA TM tissue is a bovine pericardial tissue that incorporates a novel preservation technology. The technology includes a proprietary stable-capping anti-calcification process, which permanently blocks residual aldehyde groups that are known to bind with calcium. The technology also incorporates tissue preservation with glycerol, which replaces the traditional storage in liquidbased solutions such as glutaraldehyde. The valve is sterilized using ethylene oxide and requires no rinsing prior to implantation.
Population and procedure
The population of patients undergoing surgery were patients with symptomatic aortic valve disease, operated upon by standard operative techniques (Table 1 ) [15] . Patients were offered enrollment into the COMMENCE trial by surgeons at individual investigational sites based upon an indication for surgical aortic valve replacement, an appropriate risk profile and surgical preference for a bioprosthesis. Consented patients were considered enrolled in the clinical trial after the surgeon visually inspected the aortic root, sized the aortic valve annulus and determined that the trial valve could be implanted. Patients requiring concomitant coronary artery bypass grafting, or replacement of the ascending aorta without circulatory arrest, were included. Excluded patients were those with a history of prior valve operation involving a prosthetic valve or ring that would remain in situ; concomitant valve repair or replacement of the mitral, tricuspid, or pulmonary valves; and concomitant operations involving structures outside of the heart. The operative incision and technique of AVR were left to the discretion of the surgeon investigator and included a minimally invasive 'J' or 'T' incision in the upper sternum or right mini-thoracotomy [16, 17] .
Valve recipients were maintained on antiplatelet therapy (except when contraindicated) during the initial healing stage after implant, in accordance with the ACC/AHA 2006 Guidelines for the Management of Subjects with Valvular Heart Disease [18, 19] . However, the final determination of antiplatelet and/or anticoagulation treatment was at the discretion of the surgeon.
Safety and effectiveness end-points
The primary safety end-point for the trial is the rate of implanted subjects that experience structural deterioration (SVD) of the trial valve. Secondary safety end-points included all-cause mortality, valve-related mortality, reoperation, thromboembolism (stroke, transient ischaemic attack or systemic embolism), valve thrombosis, all paravalvular leaks (PVLs), major PVL, endocarditis and new permanent pacemaker implantation within the first year of follow-up. Perioperative bleeding was defined as any intra-or post-procedural bleeding related to the implant procedure up to 3 days post-implant, which led to patient death, re-exploration or repair, prolonged hospitalization or transfusion of 3 or more units of packed red blood cells. Safety outcomes were measured using standardized end-points described in the Guidelines for Reporting M&M after Cardiac Valve Interventions and FDA reporting requirements [19] . All safety end-points were adjudicated by an independent Clinical Events Committee based on patientlevel source documents obtained from the investigational sites.
The primary effectiveness end-points in the study were improvement in New York Heart Association (NYHA) functional class and valve haemodynamic performance (effective orifice area, mean pressure gradient and PVL) at 1 year. Haemodynamic performance data were evaluated by an independent Echocardiographic Core Laboratory (BioTelemetry Research, South San Francisco, CA, USA).
Statistical analysis
Categorical variables are summarized using item counts and percentages. Continuous variables are summarized using the mean, standard deviation, minimum, and maximum. Safety outcomes were summarized for early (within 30 days of valve implant) and late (beyond 30 days) events. Early events are expressed as a percentage of the number of patients experiencing an event divided by the total number of patients. Late events are expressed as a linearized rate, which is calculated as the number of late events divided by the total number of late patient-years. Late patient-years are computed starting from postoperative Day 31 until the last followup visit (or contact) or adverse event. Additionally, Kaplan-Meier estimates are provided based on all primary and secondary safety outcomes including both early and late outcomes. Statistical analysis is undertaken by trained biostatisticians using SAS Statistical software package version 7.0. Throughout the manuscript, N is the number of patients with available data for the given parameter.
RESULTS

Demographics and baseline characteristics
The COMMENCE Trial enrolled 694 patients with 689 receiving implantation of the study device (Table 1) (Table 2 ) included systemic hypertension Table 5 . For isolated AVR, the mean aortic cross-clamp time and cardiopulmonary bypass time for full sternotomy were 67.6 ± 22.4 min and 93.0 ± 32.3 min, respectively; for upper ministernotomy, 69.7.5 ± 23.5 min and 96.4 ± 33.7 min, respectively.
Clinical events
Early clinical outcomes and actuarial event-free rates for all study valve patients are listed in Table 6 and graphically displayed in Fig. 1 . Early (30-day operative) mortality was observed in 1.2% (8 of 689), 0.4% (3 of 689) of which were adjudicated as valve related. Causes of death included cardiogenic shock (n = 2), cardiac arrest (n = 2), respiratory failure (n = 1), stroke (n = 1), pulmonary embolism (n = 1) and sudden unexplained death (n = 1). One patient required reoperation (0.1%). Fifteen patients (2.2%) experienced thromboembolic events, including stroke (n = 11, 1.6%) and 4 transient ischaemic attacks (n = 4, 0.6%). Six patients experienced perioperative bleeding (0.9%). A new permanent pacemaker was implanted in 4.7% of patients (n = 31). The mean intensive care unit and total hospital length of stay were 3.0 ± 4.1 days (median: 2) and 7.7 ± 6.2 days (median: 7), respectively.
The present data set includes 857 patient-years of follow-up, corresponding to a mean follow-up of 1.2 ± 0.7 years (range: 0-3.1). Eighteen deaths were reported beyond 30 days of the index operation (2.2%/patient-year), 6 of which were adjudicated as related to the study valve (0.6%/patient-year). Actuarial freedom from all-cause death at 1 year for all patients and for isolated AVR only was 97.6% and 98.2%, respectively; freedom from thromboembolism was 96.5% and 97.2%; and, freedom from major paravalvular leak was 99.7% and 99.8%. Actuarial freedom from all-cause death at 2 years for all patients and for isolated AVR patients was 94.3% and 95.3%; freedom from thromboembolism was 94.5% and 96.5%; and, freedom from major paravalvular leak was 99.7% and 99.8%. The patient cohort from which each parameter is calculated is 689. Five cases of late endocarditis were observed (0.6%/patientyear). Two were treated with intravenous antibiotics and recovered with complete resolution of echocardiographic findings. In 3 other patients, the valve was explanted, patient treated with antibiotics, and patients recovered without sequelae. At 2 years, actuarial freedom from endocarditis was 98.9%. No cases of structural valve deterioration, non-structural valve dysfunction, valve thrombosis or hemolysis were reported.
GENERAL ADULT CARDIAC
Haemodynamic performance by valve size over time is shown in Table 7 . The mean transvalvular pressure gradient at 2 years was 10.1 ± 4.3 mmHg and the mean effective orifice area was 1.6 ± 0.5 cm 2 . These values were maintained virtually unchanged through 2 years. None or trivial (+1) PVL was reported in 94.5% of patients at 2 years, 4.9% of patients had mild (2+) PVL, 1 patient had moderate PVL (+3). There were no patients presenting with severe PVL (+4). At 2 years, 65.7% of patients showed improvement in NYHA class, 31.0% of patients were unchanged and 3.3% of patients worsened. Overall, at 1 year, 80.7% of patients were in NYHA functional Class I (411 of 509); 17.3% in Class II (88 of 509); 1.6% in Class III (8 of 509); and, 0.4% in Class IV (2 of 509). At 2 years, 72.9% of patients were in NYHA functional Class I (175/240); 24.2% in Class II (58 of 240); 2.5% in Class III (6 of 240); and 0.4% in Class IV (1 of 240).
DISCUSSION
The COMMENCE Trial is an FDA investigational device exemption study evaluating the early safety and effectiveness of a novel bovine pericardial bioprosthetic tissue, RESILIA TM , incorporated into the Carpentier-Edwards PERIMOUNT TM Magna Ease TM aortic bioprosthetic valve platform. The study valve is identical to the standard Magna Ease valve in every way, except for the addition of the new RESILIA TM tissue and its novel integrity preservation technology.
In contrast to mechanical valves, bioprosthetic tissue valves offer the advantage of not requiring lifelong anticoagulation, with its associated risk of bleeding. However, the risks of prosthetic valve deterioration and subsequent reoperation are higher in patients with bioprosthetic valves.
Degenerative calcification is the most common cause of bioprosthetic aortic valve stenosis and SVD [20] . Younger patients have an increased risk of SVD compared with older patients (>65 years old) [7, 21] . Tissue modification strategies aimed at reducing calcium accumulation in bioprosthetic aortic valves include the use of surfactants or ethanol to remove the majority of acidic phospholipids which are sites of mineralization and calcium deposition [22, 23] . Amino-oleic acid and ethanol-based methods are currently available approaches aimed at reducing aldehyde content and tissue reactivity in bioprosthetic tissue [12, 24, 25] . RESILIA TM tissue incorporates a proprietary integrity preservation technology, which supplements the existing ThermaFix TM tissue process by integrating an additional stablecapping process that covalently binds in a permanent manner to aldehyde residuals. This is followed by glycerolization to preserve the tissue in dry storage. RESILIA TM tissue is designed to enhance long-term valve durability, allowing the valve to be stored without liquid (glutaraldehyde); therefore, the valve rinsing step during implantation is no longer necessary. Experimental evidence indicates that the novel integrity preservation technology applied during the preparation of bioprosthetic tissue reduces the accumulation of calcium in pericardial tissue [13] . The use of bioprosthetic aortic valves in patients < _65 years is supported by numerous studies [7, 9, 26] . For patients reaching the 1-and 2-year follow-up points in the COMMENCE Trial, no SVD was observed in any patient. With surgical AVR, SVD, valve thrombosis, non-structural valve dysfunction and haemolysis are rare events during the first year of follow-up. Moreover, the long-term durability for bioprosthetic valves is well characterized. Recently, Johnston et al. reported 12 569 patients who underwent AVR using the Carpentier-Edwards PERIMOUNT TM valve at the Cleveland Clinic over a 27 1 =2-year period [27] . In patients aged between 60 years and 80 years, the Kaplan-Meier estimates for SVD at 10 and 20 years were 1.5% and 8.1%, respectively. Thus, while the absence of SVD in the first 800 patient-years of follow-up in the COMMENCE trial is reassuring, it is consistent with early outcomes achieved with the predicate PERIMOUNT TM and Magna Ease TM valves. The surgical technique used for the AVR procedure in the COMMENCE trial was at the discretion of each surgeon's routine surgical practice. Thus, early and 2-year results from this trial, which enrolled 694 patients across 27 cardiac surgical sites, reflect contemporary surgical AVR outcomes. The mean STS predicted risk of mortality (2.0 ± 1.8%) and logistic EuroSCORE II (2.5 ± 2.8%) were consistent with low operative risk. Thirty-day outcomes were excellent and included an all-cause mortality rate of 1.0% (4 of 396) among isolated AVR patients and 1.2% (8 of 689) among all patients. These results compare favourably with previous studies of bioprosthetic tissue aortic valves reporting early mortality ranging from 2.8 to 7.2% [6, [28] [29] [30] . The 30-day incidence of stroke and pacemaker implantation was 1.0% and 4.1%, respectively. By comparison, in a meta-analysis of 176 studies of AVR, Biancari et al. reported operative mortality of 4.3%, stroke 2.1% and pacemaker implantation 5.9%. Moreover, haemodynamic performance, evaluated by an independent Core Laboratory, reported favourable performance of the Magna Ease TM valve manufactured with RESILIA TM tissue. Mean effective orifice area was 1.6 ± 0.5 cm 2 ; mean pressure gradient was 10.1 ± 4.3 mmHg; and PVL was: none/trivial in 97.0% of patients. Importantly, the incidence of endocarditis was low and well within expected norms. These results may be taken as a contemporary benchmark against which outcomes with transcatheter aortic valve implantation and rapid deployment aortic valve replacement can be measured.
Limitations
The COMMENCE trial was a single-arm study without an active comparator group. Thus, it is susceptible to selection and channelling biases. During the enrollment phase of the study, considerable emphasis was placed on procedural training. Nonetheless, the possibility of performance bias cannot be excluded completely. The clinical end-points were objectively defined a priori, and the outcomes were independently determined by a Clinical Events Committee and an Echocardiographic Core Laboratory. Thus, potential detection and measurement biases were mitigated but not completely eliminated. The current report is limited to primary safety and effectiveness at 2 years, with 800.9 patient-years late follow-up. Hence, additional follow-up is required to establish long-term safety and effectiveness. The COMMENCE trial will follow these patients through 5 postoperative years.
CONCLUSIONS
These data from the COMMENCE FDA investigational device exemption trial indicate acceptable early safety and effectiveness of surgical AVR with the novel RESILIA TM bovine pericardial tissue in a predominantly low-risk population. This series of 689 patients having surgical AVR in 27 centres can also serve as a contemporary benchmark for alternative aortic valve therapies.
